Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Cunniff

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pediatrics|January 11, 2023
Ecopipam for Tourette Syndrome: A Randomized TrialDonald L Gilbert, Jordan S Dubow, Timothy M Cunniff, et al.
Journal of Child and Adolescent Psychopharmacology|April 24, 2025
Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving PharmacotherapyJoseph F McGuire, George B Karkanias, Richard M Bittman, et al.
Therapeutic Advances in Neurological Disorders|March 2, 2026
Plain Language Summary of a Phase 2b Randomized Controlled Trial of Ecopipam and Its 12-Month Open-Label Extension in Children and Adolescents With Tourette SyndromeDonald L Gilbert, David J B Kim, Meredith M Miller, et al.
Movement Disorders Clinical Practice|May 12, 2025
Safety and Effect of 12-Month Ecopipam Treatment in Pediatric Patients with Tourette SyndromeDonald L Gilbert, David J B Kim, Meredith M Miller, et al.
Frontiers in Psychiatry|June 18, 2026
Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulatorsKinga K Tomczak, Jason P Swindle, Firas M Dabbous, et al.
JAMA Neurology|May 26, 2026
Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical TrialDonald L Gilbert, Sarah D Atkinson, David J B Kim, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pediatrics|January 11, 2023
Ecopipam for Tourette Syndrome: A Randomized TrialDonald L Gilbert, Jordan S Dubow, Timothy M Cunniff, et al.
Journal of Child and Adolescent Psychopharmacology|April 24, 2025
Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving PharmacotherapyJoseph F McGuire, George B Karkanias, Richard M Bittman, et al.
Therapeutic Advances in Neurological Disorders|March 2, 2026
Plain Language Summary of a Phase 2b Randomized Controlled Trial of Ecopipam and Its 12-Month Open-Label Extension in Children and Adolescents With Tourette SyndromeDonald L Gilbert, David J B Kim, Meredith M Miller, et al.
Movement Disorders Clinical Practice|May 12, 2025
Safety and Effect of 12-Month Ecopipam Treatment in Pediatric Patients with Tourette SyndromeDonald L Gilbert, David J B Kim, Meredith M Miller, et al.
Frontiers in Psychiatry|June 18, 2026
Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulatorsKinga K Tomczak, Jason P Swindle, Firas M Dabbous, et al.
JAMA Neurology|May 26, 2026
Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical TrialDonald L Gilbert, Sarah D Atkinson, David J B Kim, et al.
Pageof 1